Mata-Molanes Juan J, Sureda González Manuel, Valenzuela Jiménez Belén, Martínez Navarro Elena Mª, Brugarolas Masllorens Antonio
Plataforma de Oncología, Hospital Quirónsalud Torrevieja, Alicante, Spain.
Target Oncol. 2017 Jun;12(3):289-299. doi: 10.1007/s11523-017-0489-2.
Cytokine-induced killer (CIK) cells form under certain stimulation conditions in cultures of peripheral blood mononuclear cells (PBMCs). They are a heterogeneous immune cell population and contain a high percentage of cells with a mixed T-NK phenotype (CD3+CD56+). The ready availability of a lymphocyte source, together with the high proliferative rate and potent anti-tumor activity of CIK cells, has allowed their use as immunotherapy in a wide variety of neoplasms. Cytotoxicity mediated by CD3+CD56+ T cells depends on the major histocompatibility antigen (MHC)-independent recognition of tumor cells and the activation of signaling pathways through the natural killer group 2 member D (NKG2D) cell-surface receptor. Clinical trials have demonstrated the feasibility and efficacy of CIK cell immunotherapy even in advanced stage cancer patients or those that have not responded to first-line treatment. This review summarizes biological and technical aspects of CIK cells, as well as past and current clinical trials and future trends in this form of immunotherapy.
细胞因子诱导的杀伤细胞（CIK细胞）在外周血单个核细胞（PBMC）培养物的特定刺激条件下形成。它们是一种异质性免疫细胞群体，含有高比例的具有混合T-NK表型（CD3+CD56+）的细胞。淋巴细胞来源易于获取，加上CIK细胞的高增殖率和强大的抗肿瘤活性，使其能够作为免疫疗法应用于多种肿瘤。CD3+CD56+ T细胞介导的细胞毒性取决于对肿瘤细胞的主要组织相容性抗原（MHC）非依赖性识别以及通过自然杀伤细胞2族成员D（NKG2D）细胞表面受体激活信号通路。临床试验已证明CIK细胞免疫疗法即使在晚期癌症患者或对一线治疗无反应的患者中也是可行且有效的。本综述总结了CIK细胞的生物学和技术方面，以及这种免疫疗法过去和当前的临床试验及未来趋势。
